Evidence map›Paper›PMID 31170660›Full record

ArticleStem cell research2019

Chemical screen for epigenetic barriers to single allele activation of Oct4.

Kathryn M Headley, Katarzyna M Kedziora, Aidin Alejo, Elianna Zhi-Xiang Lai, Jeremy E Purvis, Nathaniel A Hathaway

Open access · goldAbstract read
In one paragraph

Article in Stem cell research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kathryn M HeadleyDivision of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States of America; Curriculum for Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, United States of America.
Katarzyna M KedzioraDepartment of Genetics, Curriculum for Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States of America.
Aidin AlejoDivision of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States of America.
Elianna Zhi-Xiang LaiDivision of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States of America.
Jeremy E PurvisCurriculum for Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, United States of America; Department of Genetics, Curriculum for Bioinformatics and Computational Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, United States of America.
Nathaniel A HathawayDivision of Chemical Biology and Medicinal Chemistry, Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599, United States of America; Curriculum for Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, United States of America; Lineberger Comprehensive Cancer Center, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599, United States of America. Electronic address: hathaway@unc.edu.
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer Center

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
Controlling Stem Cell Fate through Computational ModelingDP2HD091800 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PURVIS, JEREMY · 2016 to 2018
$2.3M
MECHANISM OF HP1-MEDIATED HETEROCHROMATIN ASSEMBLY AND DURABILITY IN LIVE CELLSR01GM118653 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HATHAWAY, NATHANIEL A. · 2017 to 2021
$1.7M
Training in Mechanistic, Interdisciplinary Studies of Biological SystemsT32GM119999 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RAMSDEN, DALE A · 2017 to 2021
$1.2M
NCI NIH HHS P30 CA016086NICHD NIH HHS DP2 HD091800NIGMS NIH HHS R01 GM118653NIGMS NIH HHS T32 GM119999
6 · The paper itself

Abstract

Here we utilized the chromatin in vivo assay (CiA) mouse platform to directly examine the epigenetic barriers impeding the activation of the CiA:Oct4 allele in mouse embryonic fibroblasts (MEF)s when stimulated with a transcription factor. The CiA:Oct4 allele contains an engineered EGFP reporter replacing one copy of the Oct4 gene, with an upstream Gal4 array in the promoter that allows recruitment of chromatin modifying machinery. We stimulated gene activation of the CiA:Oct4 allele by binding a transcriptional activator to the Gal4 array. As with cellular reprograming, this process is inefficient with only a small percentage of the cells re-activating CiA:Oct4 after weeks. Epigenetic barriers to gene activation potentially come from heavy DNA methylation, histone deacetylation, chromatin compaction, and other posttranslational marks (PTM) at the differentiated CiA:Oct4 allele in MEFs. Using this platform, we performed a high-throughput chemical screen for compounds that increased the efficiency of activation. We found that Azacytidine and newer generation histone deacetylase (HDAC) inhibitors were the most efficient at facilitating directed transcriptional activation of this allele. We found one hit form our screen, Mocetinostat, improved iPSC generation under transcription factor reprogramming conditions. These results separate individual allele activation from whole cell reprograming and give new insights that will advance tissue engineering.

Indexed as

AllelesDNA MethylationEpigenesis, GeneticTranscriptional ActivationAnimalsChromatinHistone Deacetylase InhibitorsInduced Pluripotent Stem CellsMiceOctamer Transcription Factor-3ChromatinHistone Deacetylase InhibitorsOctamer Transcription Factor-3Pou5f1 protein, mouseChemical screenDNMT inhibitorEpigeneticsHDAC inhibitorPharmacology

Identifiers

PMID31170660
PMCPMC6886240
OpenAlexW2945583986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.